DE60012745T2 - Neue verwendung von verbindungen als antibakterielle mittel - Google Patents
Neue verwendung von verbindungen als antibakterielle mittel Download PDFInfo
- Publication number
- DE60012745T2 DE60012745T2 DE60012745T DE60012745T DE60012745T2 DE 60012745 T2 DE60012745 T2 DE 60012745T2 DE 60012745 T DE60012745 T DE 60012745T DE 60012745 T DE60012745 T DE 60012745T DE 60012745 T2 DE60012745 T2 DE 60012745T2
- Authority
- DE
- Germany
- Prior art keywords
- use according
- proton pump
- enantiomer
- pump inhibitor
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 title claims description 26
- 239000003242 anti bacterial agent Substances 0.000 title description 13
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 41
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 40
- 229940126409 proton pump inhibitor Drugs 0.000 claims description 21
- 239000000612 proton pump inhibitor Substances 0.000 claims description 21
- 241000590002 Helicobacter pylori Species 0.000 claims description 18
- 229940037467 helicobacter pylori Drugs 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 159000000011 group IA salts Chemical class 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 4
- 229960000381 omeprazole Drugs 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- -1 piperidino, morpholino Chemical group 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000002071 phenylalkoxy group Chemical group 0.000 claims description 2
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims 1
- 229960003174 lansoprazole Drugs 0.000 claims 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims 1
- 229960005019 pantoprazole Drugs 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 description 18
- 208000035143 Bacterial infection Diseases 0.000 description 13
- 208000022362 bacterial infectious disease Diseases 0.000 description 13
- 230000003115 biocidal effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000011550 stock solution Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 206010019375 Helicobacter infections Diseases 0.000 description 6
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 6
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 6
- 229960002009 naproxen Drugs 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 description 4
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- ZIIQCSMRQKCOCT-YFKPBYRVSA-N S-nitroso-N-acetyl-D-penicillamine Chemical compound CC(=O)N[C@@H](C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-YFKPBYRVSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 0 CC(C(*)=O)c(ccc1c2)cc1ccc2OC Chemical compound CC(C(*)=O)c(ccc1c2)cc1ccc2OC 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000001272 nitrous oxide Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 150000001622 bismuth compounds Chemical class 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9902027A SE9902027D0 (sv) | 1999-06-01 | 1999-06-01 | New use |
| SE9902027 | 1999-06-01 | ||
| SE9904704 | 1999-12-21 | ||
| SE9904704A SE9904704D0 (sv) | 1999-12-21 | 1999-12-21 | New use |
| PCT/SE2000/001071 WO2000072838A1 (en) | 1999-06-01 | 2000-05-25 | New use of compounds as antibacterial agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60012745D1 DE60012745D1 (de) | 2004-09-09 |
| DE60012745T2 true DE60012745T2 (de) | 2005-09-15 |
Family
ID=26663588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60012745T Expired - Lifetime DE60012745T2 (de) | 1999-06-01 | 2000-05-25 | Neue verwendung von verbindungen als antibakterielle mittel |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US6593339B1 (https=) |
| EP (1) | EP1196155B1 (https=) |
| JP (1) | JP4818516B2 (https=) |
| KR (1) | KR100671392B1 (https=) |
| CN (1) | CN1165298C (https=) |
| AR (1) | AR024159A1 (https=) |
| AT (1) | ATE272396T1 (https=) |
| AU (1) | AU780678B2 (https=) |
| BG (1) | BG106158A (https=) |
| BR (1) | BR0011116A (https=) |
| CA (1) | CA2373653C (https=) |
| CZ (1) | CZ20014289A3 (https=) |
| DE (1) | DE60012745T2 (https=) |
| EE (1) | EE200100647A (https=) |
| HK (1) | HK1045814B (https=) |
| HU (1) | HUP0201502A3 (https=) |
| IL (1) | IL146407A0 (https=) |
| IS (1) | IS6185A (https=) |
| MX (1) | MXPA01012295A (https=) |
| NO (1) | NO20015855L (https=) |
| NZ (1) | NZ515317A (https=) |
| PL (1) | PL352744A1 (https=) |
| RU (1) | RU2252032C2 (https=) |
| SK (1) | SK17392001A3 (https=) |
| TR (1) | TR200103474T2 (https=) |
| TW (1) | TWI243672B (https=) |
| WO (1) | WO2000072838A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1126838A4 (en) | 1998-10-30 | 2005-02-16 | Nitromed Inc | NITROSIS AND NITROSYAL NON-STEROID ANTI-INFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE |
| US6852739B1 (en) | 1999-02-26 | 2005-02-08 | Nitromed Inc. | Methods using proton pump inhibitors and nitric oxide donors |
| TWI243672B (en) * | 1999-06-01 | 2005-11-21 | Astrazeneca Ab | New use of compounds as antibacterial agents |
| CA2393724A1 (en) | 1999-12-23 | 2001-06-28 | Nitromed, Inc. | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| SE0000774D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| JP4092203B2 (ja) | 2000-12-21 | 2008-05-28 | ニトロメッド，インク． | 新規のシクロオキシゲナーゼ２選択的阻害剤としての置換アリール化合物、組成物、および使用方法 |
| EP1219306A1 (en) * | 2000-12-29 | 2002-07-03 | Nicox S.A. | Compositions comprising cyclodextrins and NO- releasing drugs |
| EP2260837A1 (en) | 2001-06-01 | 2010-12-15 | Pozen, Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| SE0102993D0 (sv) | 2001-09-07 | 2001-09-07 | Astrazeneca Ab | New self emulsifying drug delivery system |
| US7781396B2 (en) * | 2002-01-31 | 2010-08-24 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated disease |
| US20040052928A1 (en) * | 2002-09-06 | 2004-03-18 | Ehud Gazit | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
| EP1336602A1 (en) * | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
| WO2003103602A2 (en) * | 2002-06-11 | 2003-12-18 | Nitromed, Inc. | Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| AU2003279622A1 (en) | 2002-06-28 | 2004-01-19 | Nitromed, Inc. | Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use |
| CA2491127A1 (en) | 2002-07-03 | 2004-01-15 | Nitromed, Inc. | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| AU2003261281A1 (en) | 2002-07-29 | 2004-02-16 | Nicox S.A. | Cyclooxygenase- 2 selective inhibitors, compositions and methods of use |
| WO2004012659A2 (en) | 2002-08-01 | 2004-02-12 | Nitromed, Inc. | Nitrosated proton pump inhibitors, compositions and methods of use |
| AU2003283096A1 (en) * | 2002-11-05 | 2004-06-07 | Merck Frosst Canada And Co. | Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors |
| US7491699B2 (en) * | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
| ATE426575T1 (de) * | 2003-01-07 | 2009-04-15 | Univ Ramot | Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben |
| SE0301880D0 (sv) * | 2003-06-25 | 2003-06-25 | Astrazeneca Uk Ltd | New drug delivery composition |
| JP5137400B2 (ja) * | 2003-06-30 | 2013-02-06 | テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． | アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法 |
| US20050054714A1 (en) * | 2003-07-17 | 2005-03-10 | Benito Munoz | Nitric oxide releasing drugs for Alzheimer's disease |
| JP4917889B2 (ja) | 2003-09-25 | 2012-04-18 | テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． | アミロイド関連疾患を処置するための組成物及びその使用方法 |
| WO2005031362A2 (en) * | 2003-10-02 | 2005-04-07 | Ramot At Tel Aviv University Ltd. | Novel antibacterial agents and methods of identifying and utilizing same |
| US8007847B2 (en) | 2004-01-13 | 2011-08-30 | Eytan Biderman | Feeding formula appliance |
| WO2006006172A2 (en) * | 2004-07-15 | 2006-01-19 | Ramot At Tel Aviv University Ltd. | Use of anti-amyloid agents for treating and typing pathogen infections |
| WO2006013552A2 (en) | 2004-08-02 | 2006-02-09 | Ramot At Tel Aviv University Ltd. | Articles of peptide nanostructures and method of forming the same |
| ATE539745T1 (de) | 2004-08-19 | 2012-01-15 | Univ Tel Aviv Future Tech Dev | Zusammensetzungen zur behandlung von amyloid- assoziierten erkrankungen |
| US7786086B2 (en) * | 2004-09-08 | 2010-08-31 | Ramot At Tel-Aviv University Ltd. | Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same |
| ATE485033T1 (de) * | 2005-07-26 | 2010-11-15 | Nicox Sa | Pharmazeutische formulierung von nitrooxy- derivaten von nsar |
| US10004828B2 (en) * | 2005-10-11 | 2018-06-26 | Romat at Tel-Aviv University Ltd. | Self-assembled Fmoc-ff hydrogels |
| US7879212B2 (en) * | 2005-11-03 | 2011-02-01 | Ramot At Tel-Aviv University Ltd. | Peptide nanostructure-coated electrodes |
| JP2007275193A (ja) * | 2006-04-04 | 2007-10-25 | Fujifilm Corp | 光プローブおよび光断層画像化装置 |
| BRPI0918492A2 (pt) | 2008-09-09 | 2015-12-01 | Astrazeneca Ab | uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo |
| EP2445499A4 (en) | 2009-06-25 | 2013-02-27 | Astrazeneca Ab | METHOD FOR TREATING A PATIENT WITH RISK OF DEVELOPING A NSAID-ASSOCIATED SPURGE |
| CN103298826A (zh) | 2010-11-15 | 2013-09-11 | 特拉维夫大学拉莫特有限公司 | 用于治疗淀粉样纤维形成相关疾病的二肽类似物 |
| UA115139C2 (uk) | 2011-12-28 | 2017-09-25 | Поузен Інк. | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту |
| CN104815330A (zh) * | 2015-05-22 | 2015-08-05 | 杜林� | 乙酸类非甾体抗炎药的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
| SE8804629D0 (sv) | 1988-12-22 | 1988-12-22 | Ab Haessle | New therapeutically active compounds |
| IL98680A0 (en) | 1991-06-30 | 1992-07-15 | Yeda Res & Dev | Hydroxamate derivatives and pharmaceutical compositions containing them |
| IT1256345B (it) * | 1992-08-20 | 1995-12-01 | Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione | |
| IT1256450B (it) | 1992-11-26 | 1995-12-05 | Soldato Piero Del | Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione |
| SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| SE9302396D0 (sv) | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
| DE69412109T2 (de) * | 1993-10-06 | 1999-01-21 | Nicox S.A., Paris | Salzetersaüreester mit entzündungshemmender und/oder schmerzlindernder wirkung und verfahren zu deren herstellung |
| AU7972294A (en) * | 1993-10-07 | 1995-05-01 | Entremed, Inc | Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents |
| SI0759899T1 (en) | 1994-05-10 | 1999-12-31 | Nicox S.A. | Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities |
| IT1282686B1 (it) | 1996-02-26 | 1998-03-31 | Nicox Sa | Composti in grado di ridurre la tossicita' da farmaci |
| US5785689A (en) | 1996-07-18 | 1998-07-28 | Act Medical, Inc. | Endoscopic catheter sheath position control |
| WO1998022117A1 (en) * | 1996-11-22 | 1998-05-28 | The Procter & Gamble Company | Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials |
| US6207855B1 (en) | 1998-06-23 | 2001-03-27 | Duke University Medical Center | Stable no-delivering compounds |
| TWI243672B (en) * | 1999-06-01 | 2005-11-21 | Astrazeneca Ab | New use of compounds as antibacterial agents |
-
2000
- 2000-05-19 TW TW089109689A patent/TWI243672B/zh not_active IP Right Cessation
- 2000-05-25 EP EP00937451A patent/EP1196155B1/en not_active Expired - Lifetime
- 2000-05-25 CN CNB008082162A patent/CN1165298C/zh not_active Expired - Fee Related
- 2000-05-25 MX MXPA01012295A patent/MXPA01012295A/es active IP Right Grant
- 2000-05-25 DE DE60012745T patent/DE60012745T2/de not_active Expired - Lifetime
- 2000-05-25 SK SK1739-2001A patent/SK17392001A3/sk unknown
- 2000-05-25 KR KR1020017015407A patent/KR100671392B1/ko not_active Expired - Fee Related
- 2000-05-25 NZ NZ515317A patent/NZ515317A/en not_active IP Right Cessation
- 2000-05-25 AU AU52623/00A patent/AU780678B2/en not_active Ceased
- 2000-05-25 HK HK02107373.0A patent/HK1045814B/en not_active IP Right Cessation
- 2000-05-25 HU HU0201502A patent/HUP0201502A3/hu unknown
- 2000-05-25 RU RU2001135826/15A patent/RU2252032C2/ru not_active IP Right Cessation
- 2000-05-25 US US09/673,007 patent/US6593339B1/en not_active Expired - Fee Related
- 2000-05-25 TR TR2001/03474T patent/TR200103474T2/xx unknown
- 2000-05-25 PL PL00352744A patent/PL352744A1/xx not_active Application Discontinuation
- 2000-05-25 CA CA2373653A patent/CA2373653C/en not_active Expired - Fee Related
- 2000-05-25 EE EEP200100647A patent/EE200100647A/xx unknown
- 2000-05-25 AT AT00937451T patent/ATE272396T1/de not_active IP Right Cessation
- 2000-05-25 JP JP2000620950A patent/JP4818516B2/ja not_active Expired - Fee Related
- 2000-05-25 IL IL14640700A patent/IL146407A0/xx not_active IP Right Cessation
- 2000-05-25 CZ CZ20014289A patent/CZ20014289A3/cs unknown
- 2000-05-25 WO PCT/SE2000/001071 patent/WO2000072838A1/en not_active Ceased
- 2000-05-25 BR BR0011116-3A patent/BR0011116A/pt not_active Application Discontinuation
- 2000-05-30 AR ARP000102672A patent/AR024159A1/es not_active Application Discontinuation
-
2001
- 2001-11-28 BG BG106158A patent/BG106158A/xx unknown
- 2001-11-29 IS IS6185A patent/IS6185A/is unknown
- 2001-11-30 NO NO20015855A patent/NO20015855L/no not_active Application Discontinuation
-
2003
- 2003-05-01 US US10/426,952 patent/US20040048917A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60012745T2 (de) | Neue verwendung von verbindungen als antibakterielle mittel | |
| DE69133348T2 (de) | Behandlung von nicht-entzündlichen darmerkrankungen | |
| DE60213407T2 (de) | Zusammensetzungen zur hemmung der angiogenese | |
| DE69725860T2 (de) | PLAN ZUR VERABREICHUNG VON H+, K+-ATPase INHIBITOREN | |
| DE69529156T2 (de) | Verwendung von amino-hydrierten chinazolinverbindungen und ihren derivaten zur entwöhnung bei drogenabhängigkeit | |
| DE60022789T2 (de) | Zusammensetzung die substituierte benzimidazole enthält | |
| DE3883606T2 (de) | Verwendung von Fluoxetin zur Behandlung des Diabetes. | |
| DE69333413T2 (de) | 5-ht2-antagonisten in der behandlung venöser zustände | |
| DE69819012T2 (de) | Pharmazeutische zusammensetzung zur reduzierung der mcp-1 proteinsynthese | |
| EP0185210A2 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten | |
| DE60026491T2 (de) | Melagatran zur behandlung von entzündungen | |
| EP0856312A1 (de) | Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten | |
| DE69917796T2 (de) | Decursin-enthaltende pharmazeutische zusammensetzungen | |
| DE69202162T2 (de) | Verwendung von Tenidap zur Senkung des Gesamtserumcholesterins, LDL-Cholesterins und Triglyceride. | |
| DE69232662T2 (de) | Verfahren zur wirkungsverstärkung von mitteln der ersten wahl bei der behandlung mehrfachresistenter zellen | |
| DE69529819T2 (de) | Neue kombination eines betablockers mit einem lokalanästhetikum | |
| EP0817623B1 (de) | Arzneistoffe zur selektiven bekämpfung von tumorgewebe | |
| EP1001756B1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
| DE3006024C2 (de) | Topisches, Indomethacin enthaltendes Arzneimittel in Salbenform | |
| DE3875637T2 (de) | Zusammensetzungen und verfahren zur behandlung von magengeschwueren. | |
| DE69721077T2 (de) | Verwendung von 2-methoxyphenyl-1-methyl-5p-methyl-benzoylpyrrol-2-acetamido-acetat zur herstellung eines antientzündungsmittels mit vorbeugung von magenhypersekretion und nierenfunktionsstörung | |
| EP2803354B1 (de) | Kombination aus Polyacrylsäure und 2-Amino-2-methylpropanol zur Verwendung in der Behandlung von Herpesinfektionen | |
| DE69007439T2 (de) | Mittel gegen Tumore. | |
| DE29918478U1 (de) | Tablettenzusammensetzung | |
| EP0455769B1 (de) | Verwendung von 7-oh-1,2-benzopyron zur herstellung eines arzneimittels zur behandlung von malignen tumoren beim menschen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |